On June 23, a meeting was held in Montreal between a pharmaceutical company and the ARSACS research team with respect to the outcome of the preclinical trial phase 11 currently underway on the ARSACS mice at the Douglas Institute. The complete results should be known in November 2015. See Meeting Summary.
The preparation required for a preclinical trial with a therapeutic molecule coming from the United States will begin soon. This test will be done on ARSACS mice in Montreal laboratories. This will be the 2nd preclinical trial funded by the Foundation. The results of the first trial are still to come.
August 9, 2013
Discussions are underway between the research team and a pharmaceutical company. A meeting is scheduled for next September with the company’s representatives.
July 3, 2013
Very positive outcomes of the first therapeutic tests on transgenic ARSACS mice. For a short study, the tests demonstrated some beneficial effect on the physical performance of the mice. Discussions are underway to determine the next step.
February 18, 2013
Following a meeting held in December 2012 with a pharmaceutical company, the Board of Directors of the Foundation and the researchers on the ARSACS project have approved the start of some therapeutic tests. In fact, the pharmaceutical company will conduct some tests on ARSACS transgenic mice starting on May 23 2013. The first test for a duration of 5 days will be done in Montreal and will be to determine if the administration of a molecule to the transgenic model mice will improve or not the physical performance of the mice.